2 weeks Ago By ABMN Staff
Brandes Investment Partners LP grew its stake in Kenvue Inc. ( NYSE:KVUE – Free Report ) by 3,620.9% during the second quarter, according to the company in its most recent 13F filing with the SEC.
The institutional investor owned 1,615,904 shares of the company’s stock after purchasing an additional 1,572,476 shares during the quarter. Brandes Investment Partners LP’s holdings in Kenvue were worth $29,407,000 as of its most recent filing with the SEC. Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE.
Manchester Capital Management LLC grew its position in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the last quarter.
Mather Group LLC. bought a new stake in Kenvue during the first quarter worth approximately $28,000. Riverview Trust Co bought a new stake in Kenvue during the first quarter worth approximately $33,000.
MV Capital Management Inc. boosted its holdings in Kenvue by 71.2% during the first quarter.
MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after buying an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in shares of Kenvue in the 1st quarter valued at approximately $33,000.
Institutional investors and hedge funds own 97.64% of the company’s stock. Kenvue Stock Performance Shares of KVUE opened at $23.
26 on Monday. The company’s fifty day moving average is $21.41 and its 200-day moving average is $20.
07. Kenvue Inc. has a 12 month low of $17.
67 and a 12 month high of $23.55. The firm has a market cap of $44.
54 billion, a price-to-earnings ratio of 29.82, a price-to-earnings-growth ratio of 2.92 and a beta of 1.
40. The company has a quick ratio of 0.68, a current ratio of 0.
99 and a debt-to-equity ratio of 0.69. Kenvue Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th.
Stockholders of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.
20. The ex-dividend date was Wednesday, August 14th. This represents a $0.
82 annualized dividend and a dividend yield of 3.53%. Kenvue’s dividend payout ratio is 105.
13%. Analyst Ratings Changes Several equities research analysts recently commented on KVUE shares. Deutsche Bank Aktiengesellschaft upped their price target on shares of Kenvue from $23.
00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Citigroup reduced their price target on shares of Kenvue from $21.
00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.
00 target price for the company. in a research report on Tuesday, September 24th. JPMorgan Chase & Co.
increased their target price on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th.
Finally, Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company.
One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $22.10.
Get Our Latest Stock Analysis on KVUE Kenvue Company Profile ( Free Report ) Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. ( NYSE:KVUE – Free Report ).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter ..
